DN-2024003

DN-2024003 is a small molecule pharmaceutical candidate developed by Daehan Nupharm, intended for the treatment of fever, pain, and inflammation. It is categorized as a generic drug within the company's research and development pipeline, representing a version of an established therapeutic agent in the antipyretic, analgesic, and anti-inflammatory class. As of early 2026, the drug was in the regulatory review phase in South Korea, with an application for item approval (NDA) having been submitted in late 2024. The molecule likely functions by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), which are key mediators in the production of prostaglandins that regulate inflammatory responses, pain signaling, and thermoregulation.